How we think - Archive
August 2016
Here are all the posts from the How we think section that were published in August 2016. If you don’t see the post you’re looking for here, try our search feature or looking in the tags index.
These archives are only from the How we think section, if you’re looking for the archive for our company news page, click here.
European prostate cancer treatment is changing - what are the opportunities for marketers?
|3rd August 2016
In this article, Consultant Jeremy Poland examines some of the key dynamics in prostate cancer multi-disciplinary teams across Europe and how the recent trends impact the opportunities available to healthcare marketers.
Products as portfolios: positioning immuno-oncology products
|8th August 2016
The last few years have seen a huge proliferation in the number of products entering the oncology space, with a lot more currently being investigated in clinical trials. Effective positioning in this situation is vital to cut through the noise, so we've outlined some key learnings from our extensive experience in this area.
The biofuel cell – breathing new life into portable electronics?
|16th August 2016
Associate Medical Copywriter Kulveer Singh explains how biofuel cells work, why they are an exciting alternative to normal battery power, and what the challenges are in implementing their use.
Immuno-oncology; bringing patients closer to treatment
|18th August 2016
What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment? Even more importantly, what do immunotherapies mean for patients who face diagnosis of advanced cancers? Senior Associate Consultants Frances Hendry and Zoe Bartley tackle these complex questions.
A stumble, but not a fall – what’s next for Opdivo?
|24th August 2016
In this article, Associate Consultant Louis Perdios talks about the immunotherapy drug Opdivo and the daunting challenges faced by BMS after disappointing results. However the future for Opdivo may not be as bleak as it seems.